Cockayne Syndrome Clinical Trial
— METABO-CSOfficial title:
Metabolic Study of Cockayne Syndrome
NCT number | NCT03044210 |
Other study ID # | 6372 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | April 4, 2017 |
Est. completion date | April 2024 |
Cockayne syndrome (CS) is related to defective DNA transcription and/or repair and belongs to the family of Nucleotide Excision Repair. It is an autosomal recessive multisystemic disorder characterized by mental retardation, microcephaly, severe growth failure with lipoatrophia, sensorial impairment, cutaneous photosensitivity, dental decay, enophtalmios. The disease is progressive causing severe impairments but there's currently no therapeutics for the disease. Growth failure, feeding difficulties and lipoatrophia are prognostic keys of CS but physiopathology is unknown. According to preliminary assays, our goal is to test the hypothesis that cachexia is due to hypometabolism. We also want to test the potential link between this basal metabolism modification and mitochondrial dysfunction and somatotrope axis, and correlation between the basal metabolism degree and global severity of the disease.
Status | Recruiting |
Enrollment | 45 |
Est. completion date | April 2024 |
Est. primary completion date | April 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 6 Months and older |
Eligibility | Cockayne patients: Inclusion criteria : - Male and female with cockayne syndrome - Age>6 months Exclusion criteria: - Intercurrent diseases - Subject in period of exclusion - Pregnancy and breastfeeding Control subjects : Inclusion criteria : - Sister or brother of Cockayne patients - Age>6 months Exclusion criteria: - Intercurrent diseases - Subject in periods of exclusion - Pregnancy and breastfeeding |
Country | Name | City | State |
---|---|---|---|
France | Centre d'Investigation Clinique | Strasbourg |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Strasbourg, France |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Rest energetic cost measured by indirect calorimetry compared to calculated Black equation | Day 0 | ||
Secondary | Rest energetic cost measured by indirect calorimetry compared to calculated theorical equations | Day 0 | ||
Secondary | Hormonal axis evaluation and mitochondrial activity measured by level of hormones and lactates/pyruvates in blood | Day 0 | ||
Secondary | Respiratory quotient measured by indirect calorimetry | Day 0 | ||
Secondary | Fat mass and lean mass measured by impedancemetry | Day 0 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00985413 -
Observational Study to Assess Natural History in Cockayne Syndrome Patients
|
N/A | |
Recruiting |
NCT05484570 -
Natural History Study for DNA Repair Disorders
|
||
Active, not recruiting |
NCT00001813 -
Examination of Clinical and Laboratory Abnormalities in Patients With Defective DNA Repair: Xeroderma Pigmentosum, Cockayne Syndrome, or Trichothiodystrophy
|
||
Completed |
NCT01142154 -
Pharmacokinetics and Safety Study of Single and Multiple Oral Doses Prodarsan™ in Patients With Cockayne Syndrome
|
Phase 1/Phase 2 | |
Recruiting |
NCT01793168 -
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
|
||
Active, not recruiting |
NCT02699190 -
LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies
|
||
Recruiting |
NCT03047369 -
The Myelin Disorders Biorepository Project
|